Immunosuppressive effect of PLGA-FK506-NPs in treatment of acute cardiac rejection via topical subcutaneous injection

• Main Authors: Cheng Deng (Author), Qiaofeng Jin (Author), Ya Wu (Author), Huiling Li (Author), Luyang Yi (Author), Yihan Chen (Author), Tang Gao (Author), Wenyuan Wang (Author), Jing Wang (Author), Qing Lv (Author), Yali Yang (Author), Jia Xu (Author), Wenpei Fu (Author), Li Zhang (Author), Mingxing Xie (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

FK506, a first-line immunosuppressant, is routinely administered orally and intravenously to inhibit activation and proliferation of T cells after heart transplantation (HT). Current administration route is not conducive enough to exert its efficacy in lymphatic system. Herein, we proposed that subc...